“Severe hypokalaemia”的搜索结果，显示 341-350 项，共有 9828 项

1. 神经科- 临床试验- 妙佑医疗国际

   ... acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) ...

2. 血液科- 临床试验- 妙佑医疗国际

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

3. 神经科- 临床试验- 妙佑医疗国际

   VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, ...

4. 血液科- 临床试验- 妙佑医疗国际

   This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or ...

5. 血液科- 临床试验- 妙佑医疗国际

   The purpose of this study is to determine the effectiveness and safety of JCAR017 in adult subjects with relapsed or refractory Chronic Lymphocytic Leukemia ( ...

6. 神经科- 临床试验- 妙佑医疗国际

   VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, ...

7. 血液科- 临床试验- 妙佑医疗国际

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

8. 血液科- 临床试验- 妙佑医疗国际

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

9. 神经科- 临床试验- 妙佑医疗国际

   VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, ...

10. 神经科- 临床试验- 妙佑医疗国际

    VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore ...